グローバルにおける癌の細胞治療市場及びパイプライン分析...市場調査レポートについてご紹介

1. Introduction to Cell Therapy
1.1 Origin of Cell Therapy
1.2 Composition of Cell Therapy

2. Introduction to Cancer Therapies
2.1 Types of Stem Cell Transplants for Treating Cancer
2.2 Dendritic Cell Therapy
2.3 Targeted Cancer Therapies

3. Cancer Cell Therapy Market Overview
3.1 Market Overview
3.2 Clinical Pipeline Insight

4. Global Cancer Cell Therapy Market Dynamics
4.1 Market Drivers
4.2 Market Challenges
4.3 Future Outlook

5. Cancer Cell Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications
5.1 Unknown Phase
5.2 Research
5.3 Preclinical
5.4 Clinical
5.5 Phase I
5.6 Phase I/II
5.7 Phase II
5.8 Phase III

6. Marketed Cancer Cell Therapy Clinical Insight & Patent Analysis

7. Suspended & Discontinued Cancer Cell Therapy Clinical Insight
7.1 No Development Reported
7.2 Discontinued
7.3 Suspended

8. Competitive Landscape
8.1 Adaptimmune
8.2 Apceth
8.3 Argos Therapeutics Inc
8.4 Celgene Cellular Therapeutics
8.5 Cellerant Therapeutics
8.6 Immunicum
8.7 Innate Pharma
8.8 Innocell Corporation
8.9 Kite Pharma
8.10 Takara Bio

Figure 1-1: Four Pillars of Global Pharmaceutical Industry
Figure 1-2: Composition of Cell Therapy
Figure 2-1: Cancer Therapies Overview
Figure 3-1: Global Cell Therapy Market (US$ Billion), 2012-2018
Figure 3-2: Global Cell Therapy Market by Indications, 2013
Figure 3-3: Global Cell Therapy Market by Region (%), 2013 & 2018
Figure 3-4: Global Cancer Cell Therapy Market (US$ Billion), 2012-2018
Figure 3-5: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 3-6: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 3-7: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 3-8: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 3-9: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 3-10: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 8-1: Adaptimmune Clinical Pipeline Insight
Figure 8-2: Apceth Clinical Pipeline Insight
Figure 8-3: Argos Therapeutics Clinical Pipeline Insight
Figure 8-4: Cellerant Clinical Pipeline Insight
Figure 8-5: Immunicum Clinical Pipeline Insight
Figure 8-6: Innate Pharma Clinical Pipeline Insight
Figure 8-7: Kite Pharma Clinical Pipeline Insight